Targeting RAS-ERK signalling in cancer: promises and challenges.
about
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical AppraisalThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersIs the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?Multifunctional DDX3: dual roles in various cancer development and its related signaling pathwaysKRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentNeoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumabMolecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Tailoring the Treatment of Melanoma: Implications for Personalized MedicineWhat links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatmentTrametinib: a MEK inhibitor for management of metastatic melanomaTargeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer CellsSmall molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signallingLong-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.RAS isoforms and mutations in cancer at a glanceThe Role of ERK1/2 in the Development of Diabetic CardiomyopathyFAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistanceDeciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious DiseasesTargeting CDK4 and CDK6: From Discovery to TherapyChronic inorganic arsenic exposure in vitro induces a cancer cell phenotype in human peripheral lung epithelial cellsDownregulation of oncogenic RAS and c-Myc expression in MOLT-4 leukaemia cells by a salicylaldehyde semicarbazone copper(II) complexEpidermal RAF prevents allergic skin diseaseBRaf signaling principles unveiled by large-scale human mutation analysis with a rapid lentivirus-based gene replacement method.Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.Relaxation oscillations and hierarchy of feedbacks in MAPK signalingLipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis.Spatially transformed fluorescence image data for ERK-MAPK and selected proteins within human epidermisKRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerSanguinarine inhibits growth and invasion of gastric cancer cells via regulation of the DUSP4/ERK pathway.Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model.MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity.Optical control of cell signaling by single-chain photoswitchable kinasesInhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targetsIsoalantolactone Enhances the Radiosensitivity of UMSCC-10A Cells via Specific Inhibition of Erk1/2 Phosphorylation.A loss-of-function genetic screening identifies novel mediators of thyroid cancer cell viability.Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.Genome-Wide Analysis of RAS/ERK Signaling Targets.
P2860
Q26744536-41294D9F-F6D4-4E3C-88DA-D8EC1FC61BBFQ26747403-0A1E992C-763E-4291-B5CB-AE9AC2FB5107Q26748741-BFEAABD2-2B3F-4076-AC3E-EAE1AFA5A9CAQ26749143-5AFEA78B-73E4-4740-A971-8CF663753243Q26751520-63872834-086B-4899-ADA8-8AEA1B15315DQ26764879-63D035AE-C793-4B95-907C-E899A7F463CBQ26766689-3B3200CF-BF85-4541-8C2C-A3A639DD07A8Q26775806-B1E569E4-3E19-43EE-8403-234A324C4E5FQ26782585-07DE9F24-97DB-4B82-9B7F-B5A0E16DB395Q26782976-AFF3154F-1885-49E0-858A-4F4E6837C91EQ26798203-467489EF-844E-4FE7-BBFA-E84B9061A2FAQ27727733-DBC9CC32-0FEF-40EB-8C25-A5EE568829CEQ27853310-BD52F8A7-3D72-4CA2-95B5-1C0B3C8426FBQ28070394-EF7BDE5B-7868-4CF2-A221-7FAFB1963C96Q28075539-355CE052-1AA2-4214-80C5-A4316BDEACBCQ28077347-818B03B6-EA58-40AA-B34D-CA0431B25E5FQ28079848-CAEC33A6-3741-4D68-BD1E-255D3862A189Q28081001-4B2A8B29-F6F0-479E-8A98-1336021DEF93Q28082912-482A46EC-A17A-4BB5-8A01-77829B79C2BEQ28394865-6E2C8FA1-F3A1-4C3D-8928-AD21F4752D03Q28821489-5E2537CA-D1E9-4ED3-83D4-8919EE21BE29Q28829587-979271B2-9FDB-43CE-A830-9D29D2B3BFA6Q30252647-F9ABFFBB-4334-416D-AFEC-2BCD9D173E42Q30275521-848F02E1-B713-4C9C-89BD-3F469AAB33A9Q30833577-D78D534D-7383-4E28-B908-902F509A174BQ30851435-7CCDC780-4B1C-458D-87B1-FD8FBDDC4F49Q31032505-64A183C6-97A0-44A3-A3CE-A63E70E3AFB2Q33566777-AE4FAC3E-7D9C-4425-973C-5CC215D0CD8AQ33624491-B65CF122-E299-49F7-9482-F59C8A495782Q33684181-A30CA385-840D-4AD0-AB89-26E3BDB85CA0Q33767369-AD3BB4EF-7CBB-41C8-BB42-C3D20ABF7C69Q33787343-F3D4A1D2-0472-48F4-A189-95BEA13C8B56Q34495412-C4C08860-B3E8-4D87-86F0-391FD2ED6702Q34552000-A276FA07-AB00-494A-8DEC-53B689D3A11DQ35552019-3DD0A4C2-83D7-4749-AB31-9DE50D9F5385Q35853333-865ABFC0-1902-40A2-9A20-002CCD74E732Q35881521-979CB705-841E-4241-B7BF-4FF5F178BDD4Q35983871-600A211A-A432-404E-9D33-4F5C0CE9A799Q36198159-8023CC92-31EB-4282-A53A-B7DD8AB74E6BQ36214657-E200654B-527F-42EB-B61F-8396253B609E
P2860
Targeting RAS-ERK signalling in cancer: promises and challenges.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Targeting RAS-ERK signalling in cancer: promises and challenges.
@en
type
label
Targeting RAS-ERK signalling in cancer: promises and challenges.
@en
prefLabel
Targeting RAS-ERK signalling in cancer: promises and challenges.
@en
P356
P1476
Targeting RAS-ERK signalling in cancer: promises and challenges.
@en
P2093
Ahmed A Samatar
Poulikos I Poulikakos
P2888
P304
P356
10.1038/NRD4281
P577
2014-12-01T00:00:00Z